BMO Capital has lowered the price target on HCA Healthcare Inc (NYSE:HCA) to $250 from $275 while keeping the Market Perform rating on the shares after its Q4 results.
- Analyst Matt Borsch notes execution was very strong, but HCA still contends with near-term issues that include uneven volumes, staffing constraints, and related wage and other inflation.
- The analyst also adds that the Q4 results are likely to continue to be volatile.
- Related: HCA Healthcare Q4 Earnings Lag Estimates, Issues FY22 Guidance.
- After the earnings, Cowen lowered the price target from $302 to $265 and kept an Outperform rating on the shares.
- The analyst updated his model by slightly lowering its EBITDA for 2022, 2023, and 2024 due to COVID costs/occupancy and deferred surgical recovery labor costs.
- Price Action: HCA shares are up 1.55% at $240.26 during the market session on the last check Monday.
